News Release

Cefepime vs piperacillin-tazobactam in adults hospitalized with acute infection

JAMA

Peer-Reviewed Publication

JAMA Network

About The Study: Among 2,511 adults hospitalized with acute infection, treatment with the antibiotic piperacillin-tazobactam did not increase the incidence of acute kidney injury or death in this randomized clinical trial. Treatment with the antibiotic cefepime resulted in more neurological dysfunction. 

Authors: Edward T. Qian, M.D., M.Sc., of Vanderbilt University Medical Center in Nashville, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jama.2023.20583)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Media advisory: This study is being released to coincide with presentation at IDWeek 2023.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2023.20583?guestAccessKey=b6319680-f2a7-465d-8780-308833742dea&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=101423


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.